Adverum Biotechnologies
ADVM
ADVM was delisted on the 8th of December, 2025.
60 hedge funds and large institutions have $48.3M invested in Adverum Biotechnologies in 2023 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 13 increasing their positions, 16 reducing their positions, and 9 closing their positions.
1,300% more call options, than puts
Call options by funds: $42K | Put options by funds: $3K
11% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 9
2% more funds holding
Funds holding: 59 → 60 (+1)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
1.14% less ownership
Funds ownership: 64.62% → 63.48% (-1.1%)
19% less repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 16
51% less capital invested
Capital invested by funds: $97.9M → $48.3M (-$49.7M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
+$1.69M |
| 2 |
BCM
BML Capital Management
Zionsville,
Indiana
|
+$584K |
| 3 |
Renaissance Technologies
New York
|
+$500K |
| 4 |
WVP
Worth Venture Partners
Fort Lee,
New Jersey
|
+$413K |
| 5 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
+$388K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$1.67M |
| 2 |
VA
VR Adviser
New York
|
-$1.3M |
| 3 |
Citigroup
New York
|
-$715K |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$518K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$428K |
ADVM Hedge Fund Activity: Q4 2023 in Review
60 of the 6,869 institutional investors tracked by Wall St. Rank reported a position in Adverum Biotechnologies (ADVM) for Q4 2023, worth a combined $48.3M — down 51% from $97.9M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new ADVM positions and 9 closed out — a net gain of 1 holder — while 13 added to existing stakes and 16 trimmed.
The largest buyer was AIGH Capital Management, adding an estimated $1.69M. The largest seller was Morgan Stanley, cutting an estimated $1.67M.
- 60 institutional investors held Adverum Biotechnologies (ADVM) as of Q4 2023, up from 59 in Q3 2023.
- Funds reported $48.3M of Adverum Biotechnologies stock for Q4 2023, down 51% quarter-over-quarter.
- 10 funds opened new Adverum Biotechnologies positions in Q4 2023 and 9 closed out, a net change of +1 holder.
- The largest Adverum Biotechnologies buyer in Q4 2023 was AIGH Capital Management, an estimated $1.69M added.
- The largest Adverum Biotechnologies seller in Q4 2023 was Morgan Stanley, an estimated $1.67M sold.
Based on aggregated 13F filings for Q4 2023.